指南与共识消化道肿瘤与早癌消化内镜

AGA临床实践更新:老年人食管和结直肠癌前病变监测

AGA Clinical Practice Update on Surveillance of Metaplastic and Premalignant Conditions of the Esophagus and Colorectum in Older Adults: Expert Review.
指南 / 共识 · Clin Gastroenterol Hepatol · 2026-08-03

美国胃肠病学会发布专家综述,针对≥65岁人群食管和结直肠癌前病变的监测提出9条最佳实践建议,强调共病评估、预期寿命工具和共同决策,个体化决定是否继续监测,并关注内镜操作的不良事件风险。

要点

  • 用共病和预期寿命工具区分监测获益与受害的老年人。
  • Barrett食管监测基于共同决策,无法耐受治疗应停止。
  • >75岁结直肠癌筛查和息肉监测应个体化,并记录决策。

核心结论

  • 老年人食管和结直肠癌前病变监测应基于共病、预期寿命和患者偏好个体化决策。

研究设计与样本

  • 美国胃肠病学会临床实践更新委员会委托并批准的专家综述,基于文献回顾和专家意见,未进行系统评价。

主要发现

  • 结肠镜可降低人群结直肠癌死亡率,但Barrett食管内镜监测的高质量数据有限。
  • 随年龄增长,结肠镜不良事件发生率升高,无论适应症。

关键数值与推荐

  • 建议1:正式评估共病和使用预期寿命工具可能有助于区分监测获益与受害的老年人。
  • 建议2:Barrett食管内镜监测应遵循当前最佳实践(成像、组织取样和监测间隔)。
  • 建议3:继续Barrett食管监测应基于共同决策,考虑共病、预期寿命、风险获益和患者偏好。
  • 建议4:使用Barrett食管异型增生进展预测工具可能有助于在个体预期寿命内定位腺癌发展的时间框架。
  • 建议5:无法耐受食管腺癌的内镜治疗、手术或肿瘤干预时,无论年龄应停止Barrett食管监测。

临床怎么用

  • 对老年人使用共病和预期寿命工具评估监测获益可能性。
  • Barrett食管监测决策需共同决策,无法耐受治疗者停止监测。
  • >75岁结肠镜决策个体化并记录在电子健康记录中。

局限性

  • 未进行系统评价,最佳实践建议未对证据质量或推荐强度进行正式评级。
  • Barrett食管内镜监测的高质量数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DESCRIPTION: The United States Census Bureau projects that the population of Americans ≥65 years old will grow 5 times faster than the total population, reaching 82 million by 2050 (23% of the population). Health care providers will increasingly need to discuss the cessation of cancer screening due to limited value in patients whose age or comorbidities preclude time to benefit from eradication of preneoplastic lesions. Although evidence supports colonoscopy's ability to reduce population-wide colorectal cancer mortality, high-quality data around endoscopic surveillance of Barrett's esophagus is more limited. In this Clinical Practice Update, we review practical approaches to assess appropriateness for colorectal cancer and esophageal cancer surveillance, the real-world yield of screening and/or surveillance in older adults, and the potential harms of surveillance. METHODS: This expert review was commissioned and approved by the American Gastroenterological Association Institute Clinical Practice Updates Committee and the American Gastroenterological Association Governing Board to provide timely guidance on a topic of high clinical importance to the American Gastroenterological Association membership, and underwent internal peer review by the Clinical Practice Updates Committee and external peer review through standard procedures of Clinical Gastroenterology and Hepatology. These Best Practice Advice statements were drawn from a review of the published literature and from expert opinion. Because systematic reviews were not performed, these Best Practice Advice statements do not carry formal ratings regarding the quality of evidence or strength of the presented considerations. BEST PRACTICE ADVICE STATEMENTS BEST PRACTICE ADVICE 1: Formal determination of comorbidities and use of life expectancy tools may help differentiate among older adults most likely to benefit vs those most likely to be harmed by surveillance. Real-world effectiveness and cost-effectiveness analysis in diverse populations would help with widespread implementation. BEST PRACTICE ADVICE 2: The goal of endoscopic surveillance in Barrett's esophagus is to detect dysplasia and adenocarcinoma at an early and treatable stage. Endoscopic surveillance of Barrett's esophagus should follow current best practices in terms of imaging, tissue acquisition, and surveillance intervals. BEST PRACTICE ADVICE 3: The choice to continue endoscopic surveillance of Barrett's esophagus should be based on shared decision-making that examines factors such as comorbidities, life expectancy, risks, and benefits, as well as patient preferences. BEST PRACTICE ADVICE 4: Utilization of tools for prediction of dysplasia progression in Barrett's esophagus may help contextualize the time frame for the development of adenocarcinoma within an individual's life expectancy. BEST PRACTICE ADVICE 5: Inability to tolerate endoscopic therapy, surgery, or oncologic interventions for esophageal adenocarcinoma should lead to cessation of Barrett's esophagus surveillance regardless of age. BEST PRACTICE ADVICE 6: The decision to continue colorectal cancer screening in individuals >75 years old should be individualized, based on an assessment of benefits, screening history, comorbidities, and risks. BEST PRACTICE ADVICE 7: The decision to continue surveillance of colorectal polyps in individuals >75 years old should be individualized, based on an assessment of benefits, polyp history, comorbidities, and risks. BEST PRACTICE ADVICE 8: With increasing age, colonoscopy is associated with a higher incidence of adverse events regardless of the indication. Therefore, the clinical decision-making process for colonoscopy should be clearly documented in the electronic health record for individuals >75 years. BEST PRACTICE ADVICE 9: Whenever possible, published studies of the use, effectiveness, deimplementation, and costs of colonoscopy in older adults should be used to inform practice decisions for patients and clinicians.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Calderwood AH, Yoshida CM, Das KK, et al. AGA Clinical Practice Update on Surveillance of Metaplastic and Premalignant Conditions of the Esophagus and Colorectum in Older Adults: Expert Review. Clin Gastroenterol Hepatol. 2026. PMID: 42545305. doi:10.1016/j.cgh.2026.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。